Exploring the Genetic and Epigenetic Factors in Leukemia and Lymphoma

Dear Colleagues,

Recent technological advances in the field of next-generation sequencing and chromatin conformation, together with refined computational tools, have greatly advanced our understanding of genetic and epigenetic alterations, leading to the establishment of new treatments to treat cancer. In the field of hematology in particular, many pioneering studies have shown that alterations of the DNA sequence and the elements that drive its transcription and translation are at the origin of cell identity, differentiation, and transformation. A better understanding of the genetic and epigenetic mechanisms that govern hematological malignancies is key to the field since it will provide new and improved strategies for prevention and personalized treatment. We are therefore pleased to invite you to contribute your original work to shed light on the molecular drivers of genetic and epigenetic aberrations and the strategies for their reversibility.

This Special Issue aims to offer an overview of the latest discoveries in the field, with particular attention to mechanistic approaches, discovery platforms, and diagnostic and therapeutic opportunities.

For this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following:

• Genetic and epigenetic alterations in hematological disease;
• Novel mechanisms of gene regulation via DNA and RNA modifications (including DNA/RNA methylation, histone modifications, RNA alternative splicing, and noncoding RNAs);
• Molecular mechanisms governing gene expression at the genetic and epigenetic levels and strategies for their reversibility;
• Computational approaches for the analysis of genetic and epigenetic mechanisms in cancer;
• Genetic and epigenetic alterations in response to environmental factors and drugs;
• Molecular profiling of genetic and epigenetic markers for the discovery of biomarkers and therapeutic targets.

Should you have any questions, require further information, or need any assistance, please do not hesitate to reach out to us. We are here to support and facilitate your participation in this Special Issue.

Thank you for your attention to this matter, and we look forward to receiving your valuable submissions. 

Dr. Francesco E. Boccalatte
Guest Editor 

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• hematology
• leukemia
• lymphoma
• epigenetics
• bioinformatics
• gene expression
• chromatin conformation